← Back to Intelligenist

Continuous PBM contract verification.

A new operational standard for plan fiduciaries · May 2026

Forensic audits run every two to three years. Cortex closes the multi-year blind spots between them by checking every claim, every quarter, against your contract, the public record, and your own formulary.

The policy-to-operation gap

Over the past five years, legislative transparency mandates and fiduciary litigation — Lewandowski v. Johnson & Johnson chief among them — have rapidly expanded plan sponsors’ access to pharmacy benefit manager disclosures. The operational tooling required to verify those disclosures has not kept pace.

Today, self-funded employers, purchasing coalitions, and state Medicaid programs rely on retrospective, sample-based audits conducted every two to three years by external audit firms. Those forensic engagements are vital for retroactive reconciliation. They also leave a structural gap: fiduciaries operate in multi-year blind spots where contract terms and claim-adjudication definitions go day-to-day unmonitored.

The bottleneck is not awareness of PBM practices. It is the sheer volume of claims. No fiduciary team can manually cross-reference millions of claims against hundreds of contract clauses and shifting formularies every quarter.

The methodology

The next generation of pharmacy benefit oversight moves from retrospective sampling to continuous, claim-level verification. Every guarantee, every operational definition, every covenant in the contract is measured against every claim the plan adjudicates — in the same cadence the plan operates, not in two-year reconciliation cycles.

This continuous monitoring framework operates across three dimensions.

i. Contract as the rulebook

Generic effective rates, specialty-drug definitions, at-risk performance thresholds, rebate pass-through terms — whatever the contract already obligates the PBM to deliver, evaluated continuously against the claims stream. Each finding traces back to the contract clause that defines it.

ii. Independent benchmarking

Continuously validating claims pricing against independent public datasets: the National Average Drug Acquisition Cost (NADAC), Actual Acquisition Cost (AAC), and federal Medicaid drug pricing data. Where the contract’s definitions diverge from the public benchmark, the gap is quantified at line-item resolution.

iii. Automated classification audit

Detecting plan-design overrides, formulary placement discrepancies, and drug reclassifications — brand-to-generic, specialty-tier gaming, NDC-level reroutes — before they distort plan spend, not two years after.

For example: a contract may report 100% rebate pass-through. Continuous verification benchmarks the manufacturer–to–PBM rebate flows against industry-standard ranges. This immediately quantifies the gap between expected market rebate rates and the actual revenues flowing back to the plan sponsor, giving fiduciaries the precise data needed to renegotiate definitions — closing the affiliated GPO loophole, for instance — in their next contract cycle.

Adjacency, not competition

This operational framework is designed to complement, not replace, existing stakeholders in the pharmacy purchasing ecosystem.

• Forensic audit firms. Continuous verification provides clean, pre-structured claim histories that enhance the speed and impact of traditional audit firms (3 Axis Advisors, Truveris, HealthPlan Data Solutions) during their comprehensive retrospective cycles. The next forensic engagement starts with the prior quarters already mapped to contract clauses.
• Transparent administrators. Standardized claim-level monitoring assists transparent PBMs (Capital Rx, Navitus, SmithRx) by providing neutral, third-party validation of their performance and migration ROI to prospective buyers.
• Coalition tooling. The method builds on and integrates with coalition-led advocacy structures, including the National Alliance of Healthcare Purchaser Coalitions (NAHPC) 340B Employer Cost Impact Calculator and the National Association of State Health Policy (NASHP) cost frameworks.

Academic and policy foundations

The methodology builds on empirical insights from public-sector oversight models and academic research.

• Ohio Department of Medicaid. The transition to a Single PBM (SPBM) model under Gainwell Technologies demonstrated how a centralized, layered oversight architecture can eliminate spread pricing and standardize claims adjudication across multiple managed care plans.
• Johns Hopkins Drug Affordability Initiative. Research from Dr. Mariana Socal and Dr. Ge Bai documenting systemic pricing distortions, rebate leakage pathways, and the fiduciary necessity of plan-level audit capabilities.
• State forensic audits. The 2018 Ohio Auditor report (Yost) that quantified an 8.8% all-drug spread and $224.8 million in extracted value, establishing the financial rationale for independent, state-level contract auditing.

Looking ahead

As we run early pilot iterations of the verification compiler over the next two quarters, the goal is to share de-identified pattern findings across mid-market employer plans and state public-sector populations. Fiduciaries, coalition leaders, and policy advisors interested in reviewing the pilot performance data or discussing contract translation standards are invited to engage.